<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320312460290</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320312460290</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Nielsen</surname><given-names>Stine E</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312460290">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Schjoedt</surname><given-names>Katrine J</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312460290">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rossing</surname><given-names>Kasper</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312460290">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Persson</surname><given-names>Frederik</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312460290">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Schalkwijk</surname><given-names>Casper G</given-names></name>
<xref ref-type="aff" rid="aff2-1470320312460290">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Stehouwer</surname><given-names>Coen DA</given-names></name>
<xref ref-type="aff" rid="aff2-1470320312460290">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Parving</surname><given-names>Hans-Henrik</given-names></name>
<xref ref-type="aff" rid="aff3-1470320312460290">3</xref>
<xref ref-type="aff" rid="aff4-1470320312460290">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rossing</surname><given-names>Peter</given-names></name>
<xref ref-type="aff" rid="aff1-1470320312460290">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1470320312460290"><label>1</label>Steno Diabetes Center, Gentofte, Denmark</aff>
<aff id="aff2-1470320312460290"><label>2</label>Department of Internal Medicine and Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, The Netherlands</aff>
<aff id="aff3-1470320312460290"><label>3</label>Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, Denmark</aff>
<aff id="aff4-1470320312460290"><label>4</label>Faculty of Health Science Aarhus University, Denmark</aff>
<author-notes>
<corresp id="corresp1-1470320312460290">Stine Elkjaer Nielsen, Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark. Email: <email>Sene@steno.dk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>14</volume>
<issue>2</issue>
<fpage>161</fpage>
<lpage>166</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Renin-angiotensin-aldosterone system (RAAS) blockade may reduce levels of biomarkers of chronic low-grade inflammation and endothelial dysfunction. We investigated the effect of spironolactone added to standard RAAS blockade on these biomarkers in an analysis of four original studies.</p>
<sec id="section1-1470320312460290">
<title>Materials and methods:</title><p>The studies were double-blind, randomised, placebo-controlled studies in 46 type 1 and 23 type 2 diabetic patients with micro- or macroalbuminuria treated with angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB), and randomised to additional treatment with spironolactone 25 mg and placebo daily for 60 days.</p></sec>
<sec id="section2-1470320312460290">
<title>Outcome measures:</title><p>Changes in inflammatory (hsCRP, s-ICAM, TNFα, IL-6, IL-8, Serum amyloid A, IL1β), endothelial dysfunction (sE-selectin, s-ICAM1, s-VCAM1, VWF, p-selectin, s-thrombomodulin) and NT-proBNP after each treatment period.</p></sec>
<sec id="section3-1470320312460290">
<title>Results:</title><p>During spironolactone treatment, u-albumin excretion rate was reduced from 605 (411–890) to 433 (295–636) mg/24 h, as previously reported. Markers of inflammation and endothelial dysfunction did not change; only changes in NT-proBNP (reduced by 14%, <italic>p</italic>=0.05) and serum amyloid A (reduced by 62%, <italic>p</italic>=0.10) were borderline significant.</p></sec>
<sec id="section4-1470320312460290">
<title>Discussions:</title><p>Our results indicate that the renoprotective effect of spironolactone when added to RAAS blockade is not mediated through anti-inflammatory pathways since markers of inflammation and endothelial dysfunction are not affected during treatment.</p></sec>
</abstract>
<kwd-group>
<kwd>Diabetes</kwd>
<kwd>inflammation</kwd>
<kwd>endothelial dysfunction</kwd>
<kwd>diabetic nephropathy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section5-1470320312460290" sec-type="intro">
<title>Introduction</title>
<p>Diabetic nephropathy develops in 30–40% of diabetic patients<sup><xref ref-type="bibr" rid="bibr1-1470320312460290">1</xref></sup> and is associated with a higher risk of other micro- and macrovascular complications: neuropathy, retinopathy and cardiovascular disease, and with increased all-cause mortality. The increased morbidity and mortality in patients with diabetic nephropathy is partly due to the development of end-stage renal disease (ESRD) and cardiovascular disease,<sup><xref ref-type="bibr" rid="bibr1-1470320312460290">1</xref></sup> but some studies have shown that it might in part also be mediated through inflammatory activity<sup><xref ref-type="bibr" rid="bibr2-1470320312460290">2</xref>,<xref ref-type="bibr" rid="bibr3-1470320312460290">3</xref></sup> and endothelial dysfunction.<sup><xref ref-type="bibr" rid="bibr4-1470320312460290">4</xref></sup></p>
<p>In patients with micro- or macroalbuminuria (urinary (u)-albumin excretion rate &gt;30 or &gt;300 mg/24 hours (h), respectively), blockade of the renin-angiotensin-aldosterone system (RAAS) has mainly focused on inhibition of the angiotensin-converting enzyme (ACE) and angiotensin II receptor blockade (ARB), which has been found to reduce the development and progression of diabetic nephropathy<sup><xref ref-type="bibr" rid="bibr5-1470320312460290">5</xref></sup> and preserve renal function.<sup><xref ref-type="bibr" rid="bibr6-1470320312460290">6</xref>,<xref ref-type="bibr" rid="bibr7-1470320312460290">7</xref></sup> In experimental studies, aldosterone has been found to cause kidney damage by inducing inflammation, fibrosis and necrosis.<sup><xref ref-type="bibr" rid="bibr8-1470320312460290">8</xref>,<xref ref-type="bibr" rid="bibr9-1470320312460290">9</xref></sup> Among patients receiving ACE or ARB blockade, 40% develop “aldosterone breakthrough” where aldosterone levels are relatively high despite RAAS treatment, and the extent of aldosterone breakthrough is related to a decline in glomerular filtration rate (GFR).<sup><xref ref-type="bibr" rid="bibr10-1470320312460290">10</xref>,<xref ref-type="bibr" rid="bibr11-1470320312460290">11</xref></sup> Both in type 1 and type 2 diabetes, spironolactone has been found to lower albuminuria and thus potentially be renoprotective when added to standard treatment including angiotensin-converting enzyme inhibitors (ACE inhibitors) or ARBs as shown in our previous studies,<sup><xref ref-type="bibr" rid="bibr12-1470320312460290">12</xref><xref ref-type="bibr" rid="bibr13-1470320312460290"/>–<xref ref-type="bibr" rid="bibr14-1470320312460290">14</xref></sup> although long-term studies are lacking.</p>
<p>In clinical trials, markers of chronic low-grade inflammation and endothelial dysfunction were shown to be reduced by spironolactone in rheumatoid arthritis<sup><xref ref-type="bibr" rid="bibr15-1470320312460290">15</xref></sup> and by eplerenone in essential hypertension.<sup><xref ref-type="bibr" rid="bibr16-1470320312460290">16</xref></sup></p>
<p>From previous long-term prospective studies we have seen that in type 1<sup>2</sup> and type 2 diabetes,<sup><xref ref-type="bibr" rid="bibr4-1470320312460290">4</xref></sup> lower levels of markers of endothelial dysfunction and inflammation are associated with a better outcome regarding cardiovascular morbidity, renal disease and all-cause mortality. Moreover, a study in patients with microalbuminuria and type 2 diabetes has shown that high levels of markers of inflammation and endothelial damage are associated with the development of diabetic nephropathy.<sup><xref ref-type="bibr" rid="bibr17-1470320312460290">17</xref></sup></p>
<p>In an attempt to evaluate the known beneficial renoprotective effect of spironolactone when added to standard renoprotective treatment including RAAS blockade, we investigated the serum levels of markers of low-grade inflammation, endothelial dysfunction and N-terminal-pro brain natriuretic peptide (NT-proBNP) in patients with diabetes and elevated urinary albumin excretion.</p>
</sec>
<sec id="section6-1470320312460290" sec-type="materials|methods">
<title>Materials and methods</title>
<p>Four studies with identical design were carried out at Steno Diabetes Center. We previously performed these four studies including patients with either type 1 or type 2 diabetes who had different levels of albuminuria (micro-, macro- and nephrotic range albuminuria) in <xref ref-type="table" rid="table1-1470320312460290">Table 1</xref>. Since the studies had identical design, we were able to pool the data for this substudy of biomarkers in diabetic patients with elevated albumin excretion rate. The study by Schjoedt et al.<sup><xref ref-type="bibr" rid="bibr18-1470320312460290">18</xref></sup> is based on merging the two studies of type 1 diabetic<sup><xref ref-type="bibr" rid="bibr12-1470320312460290">12</xref></sup> and type 2 diabetic patients<sup><xref ref-type="bibr" rid="bibr13-1470320312460290">13</xref></sup> with macroalbuminuria and adding eight more patients with nephrotic range albuminuria. This was done to investigate the subgroup of patients with nephrotic range albuminuria. The fourth study was in patients with type 1 and diabetes and microalbuminuria; this was recently published.<sup><xref ref-type="bibr" rid="bibr14-1470320312460290">14</xref></sup></p>
<table-wrap id="table1-1470320312460290" position="float">
<label>Table 1.</label>
<caption>
<p>Baseline characteristics of 69 diabetic patients. Data are given as mean (SD) or numbers</p>
</caption>
<graphic alternate-form-of="table1-1470320312460290" xlink:href="10.1177_1470320312460290-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Type1/type 2 diabetes</th>
<th align="left">46/23</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>53 (11)</td>
</tr>
<tr>
<td>Male/female</td>
<td>53/16</td>
</tr>
<tr>
<td>Macroalbuminuria</td>
<td>48</td>
</tr>
<tr>
<td><italic>Nephrotic range (&gt;2500 mg/24 h)</italic></td>
<td><italic>20</italic></td>
</tr>
<tr>
<td>Microalbuminuria</td>
<td>21</td>
</tr>
<tr>
<td>RAAS blockade</td>
<td>69</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1470320312460290"><p>RAAS: renin-angiotensin-aldosterone system.</p></fn>
</table-wrap-foot></table-wrap>
<p>The studies were randomised, double-blind, placebo-controlled, crossover studies consisting of two treatment periods. In random order, patients received spironolactone 25 mg once daily for one period of 60 days and matching placebo tablets once daily for another 60 days. During the 0- to 28-day screening period, it was ensured that patients were in optimal antihypertensive treatment. There was no drug washout period between treatment periods (‘active washout’).<sup><xref ref-type="bibr" rid="bibr19-1470320312460290">19</xref></sup> The study medication was added to the patients’ usual antihypertensive treatment, including an RAAS-blocking agent (ACE inhibitor and/or ARB) in recommended doses in all patients. The type and dose of prior antihypertensive treatment, including diuretics, remained unchanged throughout the study. At the end of each treatment period, the primary endpoint urinary albumin excretion rate, and the secondary endpoints, blood pressure, GFR and serum biomarkers of endothelial damage and inflammation were determined.</p>
<p>Dietary intake of protein and salt was not restricted; however, all patients were given written and oral information on how to lower potassium intake in their diet to lower the risk of hyperkalaemia associated with the combination of ACE inhibition or ARB and spironolactone. The study was performed according to the Declaration of Helsinki and approved by the ethical committee of Copenhagen County. All patients gave their informed consent.</p>
<p>We included 69 Caucasian diabetic patients, 46 with type 1 diabetes and 23 with type 2 diabetes. The patients had persistent micro- or macroalbuminuria (u-albumin excretion &gt;30 mg/24 h in two of three consecutive 24-h urine collections) during treatment with an ACE inhibitor or an ARB in optimal recommended doses. Patients’ ages were between 18 and 80 years.</p>
<p>Exclusion criteria were plasma (p) potassium &gt; 4.5<sup><xref ref-type="bibr" rid="bibr12-1470320312460290">12</xref>,<xref ref-type="bibr" rid="bibr13-1470320312460290">13</xref>,<xref ref-type="bibr" rid="bibr18-1470320312460290">18</xref></sup> or &gt; 4.7 mmol/l,<sup><xref ref-type="bibr" rid="bibr14-1470320312460290">14</xref></sup> pregnancy, breastfeeding, alcohol or medicine abuse, and allergy to ACE inhibitor, ARB, or spironolactone, treatment with aldosterone antagonists and GFR &lt; 30 ml/min/1.73m<sup>2</sup>. The exclusion criteria during the study were increase an in p creatinine of &gt; 35% within the first two weeks of treatment, or p potassium &gt; 5.5<sup><xref ref-type="bibr" rid="bibr12-1470320312460290">12</xref>,<xref ref-type="bibr" rid="bibr13-1470320312460290">13</xref>,<xref ref-type="bibr" rid="bibr18-1470320312460290">18</xref></sup> or 5.7<sup><xref ref-type="bibr" rid="bibr14-1470320312460290">14</xref></sup> mmol/l at any time.</p>
<sec id="section7-1470320312460290">
<title>Laboratory procedures</title>
<p>Albuminuria was determined in three consecutive 24-h urine collections, completed immediately before the end of each treatment period (Turbidimetry, Hitachi 912 System; Roche Diagnostics, Mannheim, Germany). From 24-h urine collections sodium, potassium, creatinine and urea excretion were determined (Hitachi 912 System; Roche Diagnostics).</p>
<p>To evaluate the kidney function after each treatment period, GFR was measured after a single intravenous injection of 3.7 MBq <sup>51</sup>Cr-EDTA at 8:30 a.m. by determining the radioactivity in venous blood samples taken 180, 200, 220 and 240 minutes after injection.<sup><xref ref-type="bibr" rid="bibr20-1470320312460290">20</xref></sup> The results were standardised for 1.73 m<sup>2</sup> body surface area using the patients’ surface area at the start of the study. The mean day-to-day coefficient of variation was 4% in our laboratory.</p>
<p>Blood samples for p renin and aldosterone concentrations were taken after 30 minutes of supine rest. P aldosterone was measured using a commercially available radioimmunoassay (Coat-a-Count; Diagnostic Products Corporation, Los Angeles, CA, USA).</p>
<p>The markers of endothelial dysfunction, NT-proBNP and inflammation were measured in all 21 type 1 diabetes patients with microalbuminuria,<sup><xref ref-type="bibr" rid="bibr14-1470320312460290">14</xref></sup> whereas not all markers were measured in all 69 patients (see <xref ref-type="table" rid="table2-1470320312460290">Tables 2</xref> and <xref ref-type="table" rid="table3-1470320312460290">3</xref> for the full list). <xref ref-type="table" rid="table2-1470320312460290">Table 2</xref> includes all patients, whereas <xref ref-type="table" rid="table3-1470320312460290">Table 3</xref> shows the results for the markers measured in the subset of 21 patients. All 69 patients had high-sensitivity C-reactive protein (hs-CRP), NT-proBNP, von Willebrand factor (vWf), solubleE-selectin (sE-selectin), soluble-intercellular adhesion molecule (s-ICAM1) and soluble vascular cell adhesion molecule1 (sVCAM1) measured, whereas the 21 microalbuminuric patients<sup><xref ref-type="bibr" rid="bibr14-1470320312460290">14</xref></sup> also had interleukin-6 (IL-6), interleukin-8 (IL-8), serum amyloid A (SAA), interleukin1β (IL1β), p-selectin and s-thrombomodulin measured.</p>
<table-wrap id="table2-1470320312460290" position="float">
<label>Table 2.</label>
<caption>
<p>Effect of spironolactone 25 mg treatment on all 69 patients. Data are given as means (SEM) or geometric mean (95% CI)</p>
</caption>
<graphic alternate-form-of="table2-1470320312460290" xlink:href="10.1177_1470320312460290-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left" colspan="2">Conventional antihypertensive treatment (<italic>n</italic>=69)<hr/></th>
<th align="left">Mean difference (95% CI)</th>
<th align="left"><italic>p</italic> value</th>
</tr>
<tr>
<th/>
<th align="left">+Placebo</th>
<th align="left">+Spironolactone 25 mg</th>
<th/>
<th/></tr>
</thead>
<tbody>
<tr>
<td>Urinary albumin excretion rate (mg/24 h)</td>
<td>605 (411–890)</td>
<td>433 (295–636)</td>
<td>−28% (–21 to-36)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg), 24 hour (h)</td>
<td>139 (13)</td>
<td>134 (15)</td>
<td>−5.5 (1.6)</td>
<td>0.001</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>70 (8)</td>
<td>68 (8)</td>
<td>−1.0 (1.0)</td>
<td>0.28</td>
</tr>
<tr>
<td>GFR (ml/min/1.73m<sup>2</sup>)</td>
<td>76 (28)</td>
<td>72 (28)</td>
<td>−3.5 (0.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>P aldosterone<sup>a</sup> (pg/ml)</td>
<td>31 (24–39)</td>
<td>63 (53–77)</td>
<td>51% (41–64)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td colspan="5"><bold>Biomarkers of low-grade inflammation</bold></td>
</tr>
<tr>
<td>hs-CRP (ng/ml)</td>
<td>144 (133–157)</td>
<td>148 (133–164)</td>
<td>−1% (–9 to 4)</td>
<td>0.44</td>
</tr>
<tr>
<td>s-ICAM1 (ng/ml)</td>
<td>459 (401–525)</td>
<td>462 (405–528)</td>
<td>0% (–5 to 4)</td>
<td>0.8</td>
</tr>
<tr>
<td colspan="5"><bold>Biomarkers of endothelial dysfunction</bold></td>
</tr>
<tr>
<td>sE-selectin (ng/ml)</td>
<td>52 (42–65)</td>
<td>50 (40–62)</td>
<td>−3% (–1 to 8)</td>
<td>0.13</td>
</tr>
<tr>
<td>s-ICAM1 (ng/ml)</td>
<td>459 (401–525)</td>
<td>462 (405–528)</td>
<td>0% (–5 to 4)</td>
<td>0.8</td>
</tr>
<tr>
<td>s-VCAM1 (ng/ml)</td>
<td>747 (656–851)</td>
<td>749 (659–851)</td>
<td>0% (–4 to 4)</td>
<td>0.9</td>
</tr>
<tr>
<td>P von Willebrand factor (%)</td>
<td>144 (133–157)</td>
<td>148 (134–157)</td>
<td>3 % (–9 to 4)</td>
<td>0.4</td>
</tr>
<tr>
<td colspan="5"><bold>Other biomarkers</bold></td>
</tr>
<tr>
<td>NT-proBNP (pg/ml)</td>
<td>162 (119–221)</td>
<td>139 (103–189)</td>
<td>−14% (–26 to 0)</td>
<td>0.054</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1470320312460290"><p>CI: confidence interval; GFR: glomerular filtration rate; P: plasma; hs-CRP: high-sensitivity C-reactive protein; s-ICAM1: soluble-intercellular adhesion molecule; sE-selectin: solubleE-selectin; s-VCAM1: soluble vascular cell adhesion molecule1; NT-proBNP: N-terminal-pro brain natriuretic peptide.</p></fn>
</table-wrap-foot></table-wrap>
<table-wrap id="table3-1470320312460290" position="float">
<label>Table 3.</label>
<caption>
<p>Effect of spironolactone 25 mg treatment on the subgroup of 21 microalbuminuric type 1 diabetic patients. Data are given as means (SEM) or geometric mean (95% CI)</p>
</caption>
<graphic alternate-form-of="table3-1470320312460290" xlink:href="10.1177_1470320312460290-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left" colspan="2">Conventional antihypertensive treatment (<italic>n</italic>=21)<hr/></th>
<th align="left">Mean difference (95% CI)</th>
<th align="left"><italic>p</italic> value</th>
</tr>
<tr>
<th/>
<th align="left">+Placebo</th>
<th align="left">+Spironolactone 25 mg</th>
<th/>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5"><bold>Biomarkers of low-grade inflammation</bold></td>
</tr>
<tr>
<td>TNFalpha (pg/ml)</td>
<td>9.2 (7.6–11)</td>
<td>9.3 (1.8–11)</td>
<td>0% (–11 to 9)</td>
<td>0.85</td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>1.4 (1.1–1.9)</td>
<td>1.5 (1.1–1.9)</td>
<td>2% (–18 to 24)</td>
<td>0.81</td>
</tr>
<tr>
<td>IL-8 (pg/ml)</td>
<td>8.7 (7.3–10.4)</td>
<td>8.4 (7.3–9.6)</td>
<td>−4% (–19 to 11)</td>
<td>0.56</td>
</tr>
<tr>
<td>SAA<sup>a</sup> (ng/ml)</td>
<td>3977 (1888–8373)</td>
<td>2446 (1479–4048)</td>
<td>−62% (–192 to 11)</td>
<td>0.10</td>
</tr>
<tr>
<td>s-IL1β (pg/ml)</td>
<td>2.41 (3.51–1.65)</td>
<td>2.19 (3.15–1.53)</td>
<td>10% (–7 to 29)</td>
<td>0.24</td>
</tr>
<tr>
<td colspan="5"><bold>Biomarkers of endothelial dysfunction</bold></td>
</tr>
<tr>
<td>P-selectin (ng/ml)</td>
<td>86 (72–101)</td>
<td>89 (78–102)</td>
<td>4% (–11 to 21)</td>
<td>0.58</td>
</tr>
<tr>
<td>s-thrombomodulin (ng/ml)</td>
<td>4.0 (3.5–4.5)</td>
<td>4.0 (3.5–4.6)</td>
<td>1% (–4 to 7)</td>
<td>0.64</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1470320312460290"><p>TNFalpha: tumour necrosis factor alpha; IL-6: interleukin-6; IL-8: interleukin-8; SAA: serum amyloid A; s-IL1β: serum interleukin beta.</p></fn>
</table-wrap-foot></table-wrap>
<p>All markers were measured with MSD multipanel measurements or enzyme-linked immunosorbent assay (ELISA).</p>
<p>Serum concentrations of NT-proBNP were analysed on the Elecsys 2010 platform by an electrochemiluminescence method.<sup><xref ref-type="bibr" rid="bibr21-1470320312460290">21</xref></sup> Hs-CRP and vWf were measured with highly sensitive sandwich immunoassays and s-VCAM-1, s-ICAM-1 and sE-selectin by use of commercially available ELISA kits. All measurements of the biomarkers were performed in serum except vWf, which was measured in p.</p>
<p>The intra-assay variation in our analyses was: IL-1β: 14.8%, IL-6: 5.3%, IL-8: 5.6%, tumour necrosis factor (TNF)-α: 5.0%, sE-selectin 4.0%, p-selectin: 4.7%, s-thrombomodulin: 3.9%, vWF: 3.1%, CRP: 4.5%, SAA: 3.7%, s-ICAM1: 2.8%, s-VCAM: 2.7% and NT-proBNP: 4.9%. Interassay variation was: IL-1β: 28.9%, IL-6: 13.6%, IL-8: 8.5%, TNF-α: 9.1%, sE-selectin 7.0%, p-selectin: 8.5%, s-Thrombomodulin: 7.1%, vWF: 7.7%, CRP: 4.1%, SAA: 10.8%, s-ICAM1: 5.2%, s-VCAM: 5.8% and NT-proBNP: not done. All samples were measured on one plate (for each marker).</p>
</sec></sec>
<sec id="section8-1470320312460290">
<title>Statistical analysis</title>
<p>Normally distributed variables are expressed as mean SD or mean SEM. Changes in variables between visits are expressed as means with 95% confidence interval (CI). Albuminuria and markers of inflammation, endothelial dysfunction and NT-proBNP were logarithmically transformed before statistical analysis owing to their skewed distribution and are given as geometric means (95% CI). Changes in these variables during treatment with spironolactone as compared to placebo are expressed in percentages. All comparisons of normally or log normally distributed parameters were performed with a paired Student’s <italic>t</italic> test. Comparisons of urine albumin excretion and tubular markers between treatment periods were done using paired samples Student’s <italic>t</italic> test. Data were evaluated using SPSS version 14.0 (SPSS, Chicago, IL, USA).</p>
</sec>
<sec id="section9-1470320312460290" sec-type="results">
<title>Results</title>
<p>Sixty-nine diabetic patients were randomised in the study and all completed the study. Mean age was 53 (11) years and 16 were female. Forty-six had type 1 diabetes and 23 had type 2 diabetes (<xref ref-type="table" rid="table1-1470320312460290">Tables 1</xref> and <xref ref-type="table" rid="table2-1470320312460290">2</xref>). The patients had either micro- (<italic>n</italic>=21) or macroalbuminuria (<italic>n</italic>=48), of whom 20 patients had nephrotic range albuminuria (u-albumin excretion &gt; 2500 mg/24 h). All patients received RAAS blocking agents and stable doses of diuretics. There were no changes in antihypertensive medication during the entire study period.</p>
<p>As previously published, spironolactone treatment reduced the primary endpoint, urinary albumin excretion rate, measured in three consecutive 24-h urine collections, by 28%, from 605 mg/24 h to 433 mg/24 h (<italic>p</italic> &lt; 0.001)<sup><xref ref-type="bibr" rid="bibr12-1470320312460290">12</xref><xref ref-type="bibr" rid="bibr13-1470320312460290"/>–<xref ref-type="bibr" rid="bibr14-1470320312460290">14</xref>,<xref ref-type="bibr" rid="bibr18-1470320312460290">18</xref></sup> (<xref ref-type="table" rid="table2-1470320312460290">Table 2</xref>). During treatment, p aldosterone was significantly increased, from 31 (24–39) pg/ml to 63 (53–77) pg/ml, <italic>p</italic>&lt;0.001.</p>
<p>The data on all 69 patients and biomarkers are shown in <xref ref-type="table" rid="table2-1470320312460290">Table 2</xref>. We found that the markers of low-grade inflammation hs-CRP and s-ICAM1 did not change during spironolactone treatment compared to placebo, <italic>p</italic> = 0.4 and <italic>p</italic> = 0.8, respectively. The biomarkers of endothelial dysfunction, sE-selectin, s-ICAM1, s-VCAM1 and p-vWF did not change either; they increased slightly by around 0 to 3 %, <italic>p</italic> &gt; 0.4. NT-proBNP levels decreased by 14% (–26 to 0, <italic>p</italic> = 0.054) during spironolactone treatment.</p>
<p>In the study of 21 microalbuminuric patients (<xref ref-type="table" rid="table3-1470320312460290">Table 3</xref>), SAA decreased with 62% during spironolactone treatment, although not significantly (<italic>p</italic> = 0.1). The other markers of low-grade inflammation, TNFα, IL-6, IL-8 and IL1beta, did not change at all, i.e. were not affected by spironolactone treatment (<italic>p</italic> &gt; 0.24). Regarding the biomarkers of endothelial dysfunction; s-P-selectin and s-thrombomodulin, spironolactone did not affect the levels of these either (<italic>p</italic> &gt; 0.5). There was no effect on measured biomarkers when stratifying patients into those with good response of spironolactone treatment (largest decrease in u-albumin excretion during treatment) or the largest changes in p-aldosterone levels (data not shown).</p>
</sec>
<sec id="section10-1470320312460290" sec-type="discussion">
<title>Discussion</title>
<p>We performed four randomised double-blind placebo-controlled cross-over intervention studies with spironolactone treatment in diabetic patients with elevated urinary albumin excretion already on RAAS blockade with ACE inhibitor or ARB. Changes in markers of inflammation, endothelial dysfunction and NT-proBNP were investigated in order to see if reduction in albuminuria was associated with changes in these markers. The intervention with spironolactone did not affect the markers of inflammation, endothelial dysfunction or NT-proBNP significantly. This was despite a significant reduction in albuminuria by spironolactone.</p>
<p>Aldosterone induces pro-sclerotic factors such as transforming growth factor (TGF)-β1 and decreased macrophage infiltration leading to renal fibrosis and urinary albumin excretion.</p>
<p>During treatment with an ACE inhibitor or an ARB, aldosterone secretion is initially suppressed, but 40% of all patients have “aldosterone escape phenomenon”<sup><xref ref-type="bibr" rid="bibr22-1470320312460290">22</xref></sup> or more correctly “aldosterone breakthrough.”<sup><xref ref-type="bibr" rid="bibr10-1470320312460290">10</xref></sup> Therefore, it has been considered appropriate to block the effects of aldosterone by adding spironolactone to recommended treatment with ACE inhibitors or ARBs. Based on animal studies, the mechanism for the additional effect on urinary albumin excretion during spironolactone treatment has been suggested to be reduced production of the mentioned pro-sclerotic factors.<sup><xref ref-type="bibr" rid="bibr9-1470320312460290">9</xref></sup></p>
<p>In a previous post-hoc analysis of the IRMA2 studies, we analysed the value of inflammation markers (hs-CRP, IL-6, fibrinogen) and endothelial dysfunction markers (vWf, s-VCAM-1, s-ICAM-1, sE-selectin) for the prediction of progression to diabetic nephropathy (u-albumin&gt;300 mg/24 h). We found that especially markers of endothelial dysfunction were shown to be independently associated with progression of kidney disease.<sup><xref ref-type="bibr" rid="bibr17-1470320312460290">17</xref></sup> From this it seems reasonable to assume that by diminishing levels of endothelial dysfunction, the progression or initiation of diabetic nephropathy is inhibited.</p>
<p>Blockade of the RAAS with the ACE-inhibitor enalapril or ARB irbesartan in high-risk patients (coronary artery disease or type 2 diabetes and microalbuminuria) has been shown to affect some markers of low-grade inflammation and endothelial dysfunction in a favourable way.<sup><xref ref-type="bibr" rid="bibr23-1470320312460290">23</xref>,<xref ref-type="bibr" rid="bibr24-1470320312460290">24</xref></sup> Both studies used maximally effective doses of irbesartan or losartan. However, not all markers of inflammation and endothelial dysfunction were reduced; five out of eight biomarkers in the subgroup analysis of the IRMA2 study mentioned above<sup><xref ref-type="bibr" rid="bibr24-1470320312460290">24</xref></sup> by Persson et al. were not affected by irbesartan treatment (sICAM1, sVCAM1, sE-selectin, TGFβ, AGE-peptides). In experimental settings it has been shown that aldosterone antagonism reduces the production of proinflammatory cytokines (using spironolactone)<sup><xref ref-type="bibr" rid="bibr25-1470320312460290">25</xref></sup> and attenuates renal damage and inflammation (using eplerenone).<sup><xref ref-type="bibr" rid="bibr26-1470320312460290">26</xref></sup> Furthermore, spironolactone has been shown to prevent diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.<sup><xref ref-type="bibr" rid="bibr27-1470320312460290">27</xref></sup></p>
<p>These results conflict partly with our study in that we did not find an effect on inflammatory or endothelial markers. However, in the above-mentioned clinical studies<sup><xref ref-type="bibr" rid="bibr23-1470320312460290">23</xref>,<xref ref-type="bibr" rid="bibr24-1470320312460290">24</xref></sup> high doses of RAAS blockade were used; this is in contrast to our study, which used the lowest dose of spironolactone on top of RAAS blockade. This dose was, however, sufficient to provide additional renoprotection, e.g. diminish urinary albumin excretion. Moreover, we added spironolactone/placebo on top of maximal antihypertensive and renoprotective treatment whereas in the IRMA2 study the patients were only prescribed either placebo or irbesartan on top of non-RAAS blocking antihypertensive agents.<sup><xref ref-type="bibr" rid="bibr24-1470320312460290">24</xref></sup> This means that in our study patients might already receive maximal “anti-inflammatory” treatment during the placebo period, and therefore the design of the present study might not be optimal to evaluate the individual effect of spironolactone.</p>
<p>Others found, similar to our results, no effect of spironolactone treatment (12.5 mg–50 mg) on hs-CRP in patients with heart disease.<sup><xref ref-type="bibr" rid="bibr28-1470320312460290">28</xref></sup> NT-proBNP was not significantly reduced during treatment. The lack of changes in markers of inflammation and endothelial dysfunction could indicate that the renoprotective effect of spironolactone 25 mg is not mediated through anti-inflammatory or endothelial function-improving pathways. We cannot exclude, however, that changes in inflammatory or endothelial markers in the tissues are insufficiently reflected by the values measured in serum. This needs further testing in other studies.</p>
<p>In our study aldosterone levels were compensatorily increased during spironolactone treatment as also seen in other clinical studies<sup><xref ref-type="bibr" rid="bibr18-1470320312460290">18</xref></sup>; this could also contribute to inflammation and endothelial dysfunction via pathways not blocked by spironolactone, although we did not see an increase in markers of inflammation and endothelial dysfunction in the present study. Previous studies have demonstrated that usage of spironolactone is safe and beneficial.<sup><xref ref-type="bibr" rid="bibr29-1470320312460290">29</xref>,<xref ref-type="bibr" rid="bibr30-1470320312460290">30</xref></sup></p>
<p>In conclusion, our study shows that adding spironolactone 25 mg daily to treatment with RAAS blockade in diabetic patients with elevated urinary albumin excretion does not affect markers of endothelial damage, inflammation or NT-proBNP.</p>
</sec>
</body>
<back>
<ack><p>We greatly appreciate the work of our lab technicians: BR Jensen, TR Juhl, AG Lundgaard and UM Smidt.</p></ack>
<fn-group>
<fn fn-type="conflict"><label>Conflict of interest</label><p>None declared.</p></fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This work was supported in part by EU Funding through SysKID (HEALTH–F2–2009–241544).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320312460290">
<label>1.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Parving</surname><given-names>H-H</given-names></name>
<name><surname>Mauer</surname><given-names>M</given-names></name>
<name><surname>Ritz</surname><given-names>E</given-names></name>
</person-group>. <article-title>Diabetic nephropathy</article-title>. In: <person-group person-group-type="editor">
<name><surname>Brenner</surname><given-names>BM</given-names></name>
</person-group> (ed.) <source>Brenner &amp; Rector’s the kidney</source>. <edition>8th ed.</edition> <publisher-loc>Boston, USA</publisher-loc>: <publisher-name>WB Saunders</publisher-name>, <year>2008</year>, pp.<fpage>1265</fpage>–<lpage>1298</lpage></citation>
</ref>
<ref id="bibr2-1470320312460290">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Astrup</surname><given-names>AS</given-names></name>
<name><surname>Tarnow</surname><given-names>L</given-names></name>
<name><surname>Pietraszek</surname><given-names>L</given-names></name>
<etal/></person-group>. <article-title>Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: Association with mortality and decline of glomerular filtration rate</article-title>. <source>Diabetes Care</source> <year>2008</year>; <volume>31</volume>: <fpage>1170</fpage>–<lpage>1176</lpage>.</citation>
</ref>
<ref id="bibr3-1470320312460290">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stehouwer</surname><given-names>CDA</given-names></name>
<name><surname>Donker</surname><given-names>AJM</given-names></name>
</person-group>. <article-title>Urinary albumin excretion and cardiovascular disease risk in diabetes mellitus: Is endothelial dysfunction the missing link?</article-title> <source>J Nephrol</source> <year>1993</year>; <volume>6</volume>: <fpage>72</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr4-1470320312460290">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stehouwer</surname><given-names>CD</given-names></name>
<name><surname>Gall</surname><given-names>MA</given-names></name>
<name><surname>Twisk</surname><given-names>JW</given-names></name>
<etal/></person-group>. <article-title>Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death</article-title>. <source>Diabetes</source> <year>2002</year>; <volume>51</volume>: <fpage>1157</fpage>–<lpage>1165</lpage>.</citation>
</ref>
<ref id="bibr5-1470320312460290">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marre</surname><given-names>M</given-names></name>
<name><surname>Chatellier</surname><given-names>G</given-names></name>
<name><surname>Leblanc</surname><given-names>H</given-names></name>
<etal/></person-group>. <article-title>Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria</article-title>. <source>Br Med J</source> <year>1988</year>; <volume>297</volume>: <fpage>1092</fpage>–<lpage>1095</lpage>.</citation>
</ref>
<ref id="bibr6-1470320312460290">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mathiesen</surname><given-names>ER</given-names></name>
<name><surname>Hommel</surname><given-names>E</given-names></name>
<name><surname>Hansen</surname><given-names>HP</given-names></name>
<etal/></person-group>. <article-title>Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria</article-title>. <source>Br Med J</source> <year>1999</year>; <volume>319</volume>: <fpage>24</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr7-1470320312460290">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gurley</surname><given-names>SB</given-names></name>
<name><surname>Coffman</surname><given-names>TM</given-names></name>
</person-group>. <article-title>The renin-angiotensin system and diabetic nephropathy</article-title>. <source>Semin Nephrol</source> <year>2007</year>; <volume>27</volume>: <fpage>144</fpage>–<lpage>152</lpage>.</citation>
</ref>
<ref id="bibr8-1470320312460290">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hostetter</surname><given-names>TH</given-names></name>
<name><surname>Rosenberg</surname><given-names>ME</given-names></name>
<name><surname>Ibrahim</surname><given-names>HN</given-names></name>
<etal/></person-group>. <article-title>Aldosterone in progressive renal disease</article-title>. <source>Semin Nephrol</source> <year>2001</year>; <volume>21</volume>: <fpage>573</fpage>–<lpage>579</lpage>.</citation>
</ref>
<ref id="bibr9-1470320312460290">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schrier</surname><given-names>RW</given-names></name>
<name><surname>Masoumi</surname><given-names>A</given-names></name>
<name><surname>Elhassan</surname><given-names>E</given-names></name>
</person-group>. <article-title>Aldosterone: Role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome</article-title>. <source>Clin J Am Soc Nephrol</source> <year>2010</year>; <volume>5</volume>: <fpage>1132</fpage>–<lpage>1140</lpage>.</citation>
</ref>
<ref id="bibr10-1470320312460290">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schrier</surname><given-names>RW</given-names></name>
</person-group>. <article-title>Aldosterone ‘escape’ vs ‘breakthrough’</article-title>. <source>Nat Rev Nephrol</source> <year>2010</year>; <volume>6</volume>: <fpage>61</fpage>.</citation>
</ref>
<ref id="bibr11-1470320312460290">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schjoedt</surname><given-names>KJ</given-names></name>
<name><surname>Andersen</surname><given-names>S</given-names></name>
<name><surname>Rossing</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate</article-title>. <source>Diabetologia</source> <year>2004</year>; <volume>47</volume>: <fpage>1936</fpage>–<lpage>1939</lpage>.</citation>
</ref>
<ref id="bibr12-1470320312460290">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schjoedt</surname><given-names>KJ</given-names></name>
<name><surname>Rossing</surname><given-names>K</given-names></name>
<name><surname>Juhl</surname><given-names>TR</given-names></name>
<etal/></person-group>. <article-title>Beneficial impact of spironolactone in diabetic nephropathy</article-title>. <source>Kidney Int</source> <year>2005</year>; <volume>68</volume>: <fpage>2829</fpage>–<lpage>2836</lpage>.</citation>
</ref>
<ref id="bibr13-1470320312460290">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rossing</surname><given-names>K</given-names></name>
<name><surname>Schjoedt</surname><given-names>KJ</given-names></name>
<name><surname>Smidt</surname><given-names>UM</given-names></name>
<etal/></person-group>. <article-title>Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study</article-title>. <source>Diabetes Care</source> <year>2005</year>; <volume>28</volume>: <fpage>2106</fpage>–<lpage>2112</lpage>.</citation>
</ref>
<ref id="bibr14-1470320312460290">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>SE</given-names></name>
<name><surname>Persson</surname><given-names>F</given-names></name>
<name><surname>Frandsen</surname><given-names>E</given-names></name>
<etal/></person-group>. <article-title>Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: A randomized placebo-controlled crossover study</article-title>. <source>Diabet Med</source> <year>2012</year>; <volume>29</volume>: <fpage>e184</fpage>–<lpage>e190</lpage>. DOI: <pub-id pub-id-type="doi">10.1111/j.1464-5491.2012.03585.x</pub-id>.</citation>
</ref>
<ref id="bibr15-1470320312460290">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Syngle</surname><given-names>A</given-names></name>
<name><surname>Vohra</surname><given-names>K</given-names></name>
<name><surname>Kaur</surname><given-names>L</given-names></name>
<etal/></person-group>. <article-title>Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis</article-title>. <source>Scand J Rheumatol</source> <year>2009</year>; <volume>38</volume>: <fpage>15</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr16-1470320312460290">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Savoia</surname><given-names>C</given-names></name>
<name><surname>Touyz</surname><given-names>RM</given-names></name>
<name><surname>Amiri</surname><given-names>F</given-names></name>
<etal/></person-group>. <article-title>Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients</article-title>. <source>Hypertension</source> <year>2008</year>; <volume>51</volume>: <fpage>432</fpage>–<lpage>439</lpage>.</citation>
</ref>
<ref id="bibr17-1470320312460290">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Persson</surname><given-names>F</given-names></name>
<name><surname>Rossing</surname><given-names>P</given-names></name>
<name><surname>Hovind</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study</article-title>. <source>Scand J Clin Lab Invest</source> <year>2008</year>; <volume>68</volume>: <fpage>731</fpage>–<lpage>738</lpage>.</citation>
</ref>
<ref id="bibr18-1470320312460290">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schjoedt</surname><given-names>KJ</given-names></name>
<name><surname>Rossing</surname><given-names>K</given-names></name>
<name><surname>Juhl</surname><given-names>TR</given-names></name>
<etal/></person-group>. <article-title>Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy</article-title>. <source>Kidney Int</source> <year>2006</year>; <volume>70</volume>: <fpage>536</fpage>–<lpage>542</lpage>.</citation>
</ref>
<ref id="bibr19-1470320312460290">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sibbald</surname><given-names>B</given-names></name>
<name><surname>Roberts</surname><given-names>C</given-names></name>
</person-group>. <article-title>Understanding controlled trials. Crossover trials</article-title>. <source>Br Med J</source> <year>1998</year>; <volume>316</volume>: <fpage>1719</fpage>.</citation>
</ref>
<ref id="bibr20-1470320312460290">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bröchner-Mortensen</surname><given-names>J</given-names></name>
<name><surname>Rödbro</surname><given-names>P</given-names></name>
</person-group>. <article-title>Selection of routine method for determination of glomerular filtration rate in adult patients</article-title>. <source>Scand J Clin Lab Invest</source> <year>1976</year>; <volume>36</volume>: <fpage>35</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr21-1470320312460290">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sokoll</surname><given-names>LJ</given-names></name>
<name><surname>Baum</surname><given-names>H</given-names></name>
<name><surname>Collinson</surname><given-names>PO</given-names></name>
<etal/></person-group>. <article-title>Multicenter analytical performance evaluation of the Elecsys proBNP assay</article-title>. <source>Clin Chem Lab Med</source> <year>2004</year>; <volume>42</volume>: <fpage>965</fpage>–<lpage>972</lpage>.</citation>
</ref>
<ref id="bibr22-1470320312460290">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sato</surname><given-names>A</given-names></name>
<name><surname>Hayashi</surname><given-names>K</given-names></name>
<name><surname>Naruse</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Effectiveness of aldosterone blockade in patients with diabetic nephropathy</article-title>. <source>Hypertension</source> <year>2003</year>; <volume>41</volume>: <fpage>64</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr23-1470320312460290">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schieffer</surname><given-names>B</given-names></name>
<name><surname>Bunte</surname><given-names>C</given-names></name>
<name><surname>Witte</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease</article-title>. <source>J Am Coll Cardiol</source> <year>2004</year>; <volume>44</volume>: <fpage>362</fpage>–<lpage>368</lpage>.</citation>
</ref>
<ref id="bibr24-1470320312460290">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Persson</surname><given-names>F</given-names></name>
<name><surname>Rossing</surname><given-names>P</given-names></name>
<name><surname>Hovind</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: An IRMA 2 substudy</article-title>. <source>Diabetes</source> <year>2006</year>; <volume>55</volume>: <fpage>3550</fpage>–<lpage>3555</lpage>.</citation>
</ref>
<ref id="bibr25-1470320312460290">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hansen</surname><given-names>PR</given-names></name>
<name><surname>Rieneck</surname><given-names>K</given-names></name>
<name><surname>Bendtzen</surname><given-names>K</given-names></name>
</person-group>. <article-title>Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells</article-title>. <source>Immunol Lett</source> <year>2004</year>; <volume>91</volume>: <fpage>87</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr26-1470320312460290">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blasi</surname><given-names>ER</given-names></name>
<name><surname>Rocha</surname><given-names>R</given-names></name>
<name><surname>Rudolph</surname><given-names>AE</given-names></name>
<etal/></person-group>. <article-title>Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats</article-title>. <source>Kidney Int</source> <year>2003</year>; <volume>63</volume>: <fpage>1791</fpage>–<lpage>1800</lpage>.</citation>
</ref>
<ref id="bibr27-1470320312460290">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Han</surname><given-names>SY</given-names></name>
<name><surname>Kim</surname><given-names>CH</given-names></name>
<name><surname>Kim</surname><given-names>HS</given-names></name>
<etal/></person-group>. <article-title>Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats</article-title>. <source>J Am Soc Nephrol</source> <year>2006</year>; <volume>17</volume>: <fpage>1362</fpage>–<lpage>1372</lpage>.</citation>
</ref>
<ref id="bibr28-1470320312460290">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Godfrey</surname><given-names>V</given-names></name>
<name><surname>Farquharson</surname><given-names>CA</given-names></name>
<name><surname>Macdonald</surname><given-names>JE</given-names></name>
<etal/></person-group>. <article-title>Effect of spironolactone on C-reactive protein levels in patients with heart disease</article-title>. <source>Int J Cardiol</source> <year>2007</year>; <volume>117</volume>: <fpage>282</fpage>–<lpage>284</lpage>.</citation>
</ref>
<ref id="bibr29-1470320312460290">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bianchi</surname><given-names>S</given-names></name>
<name><surname>Bigazzi</surname><given-names>R</given-names></name>
<name><surname>Campese</surname><given-names>VM</given-names></name>
</person-group>. <article-title>Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease</article-title>. <source>Kidney Int</source> <year>2006</year>; <volume>70</volume>: <fpage>2116</fpage>–<lpage>2123</lpage>.</citation>
</ref>
<ref id="bibr30-1470320312460290">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tylicki</surname><given-names>L</given-names></name>
<name><surname>Rutkowski</surname><given-names>P</given-names></name>
<name><surname>Renke</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial</article-title>. <source>Am J Kidney Dis</source> <year>2008</year>; <volume>52</volume>: <fpage>486</fpage>–<lpage>493</lpage>.</citation>
</ref></ref-list>
</back>
</article>